VALGAMAX 450MG

About

VALGAMAX 450MG contains Valganciclovir, an antiviral medication used for the treatment and prevention of cytomegalovirus (CMV) disease. It is a prodrug of ganciclovir, meaning it is converted into ganciclovir in the body after oral administration. Ganciclovir works by inhibiting viral DNA synthesis, thereby preventing CMV replication. VALGAMAX 450MG is particularly useful in immunocompromised patients, such as those with AIDS or organ transplant recipients, who are at high risk for CMV infection. Its oral bioavailability and once-daily dosing regimen offer a significant advantage over intravenous ganciclovir, improving patient convenience and adherence while providing comparable efficacy. It plays a crucial role in managing a potentially severe and life-threatening viral infection.

Uses

• Treatment of CMV retinitis in AIDS patients
• Prevention of CMV disease in organ transplant recipients
• Prophylaxis against CMV disease in high-risk patients
• Management of other CMV infections

Directions For Use

Take orally with food. Dosage and duration vary based on indication, patient weight, and renal function, as prescribed by a physician.

Benefits

• Effective against cytomegalovirus (CMV)
• High oral bioavailability, convenient dosing
• Reduces the risk of CMV disease in transplant patients
• Treats CMV retinitis, preserving vision
• Comparable efficacy to intravenous ganciclovir
• Improves patient adherence to therapy

Side Effects

• Leukopenia (low white blood cell count)
• Neutropenia (low neutrophil count)
• Thrombocytopenia (low platelet count)
• Anemia (low red blood cell count)
• Nausea
• Diarrhea
• Vomiting
• Abdominal pain
• Headache
• Fever
• Peripheral neuropathy
• Renal impairment

Safety Measures

• Alcohol - Alcohol consumption should be avoided or minimized as it can exacerbate side effects, particularly those affecting the liver or bone marrow, and may compromise immune function.
• Pregnancy - VALGAMAX is teratogenic and embryotoxic in animal studies. It should not be used during pregnancy unless the potential benefits clearly outweigh the risks, and effective contraception is essential for women of childbearing potential.
• Breastfeeding - Breastfeeding is not recommended during treatment with VALGAMAX due to the potential for serious adverse reactions in the infant.
• Liver - Use with caution in patients with liver conditions. While primarily renally excreted, liver function should be monitored, especially if other hepatotoxic drugs are co-administered.
• Kidney - VALGAMAX requires dose adjustment in patients with renal impairment. Close monitoring of kidney function is essential, and dosage should be reduced accordingly to prevent toxicity.
• Lung - No specific contraindications related to lung conditions, but overall patient health and potential drug interactions should always be considered, especially in immunocompromised patients.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.